Nuveen Asset Management LLC reduced its holdings in shares of Agilent Technologies, Inc. (NYSE:A - Free Report) by 6.8% in the fourth quarter, according to its most recent filing with the SEC. The fund owned 1,065,585 shares of the medical research company's stock after selling 77,690 shares during the period. Nuveen Asset Management LLC owned about 0.37% of Agilent Technologies worth $143,151,000 at the end of the most recent quarter.
Other institutional investors also recently bought and sold shares of the company. Meridiem Capital Partners LP purchased a new position in shares of Agilent Technologies in the 4th quarter valued at $29,492,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its stake in shares of Agilent Technologies by 4.3% in the fourth quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 84,220 shares of the medical research company's stock worth $11,314,000 after buying an additional 3,466 shares during the last quarter. LMR Partners LLP boosted its stake in shares of Agilent Technologies by 56.0% in the fourth quarter. LMR Partners LLP now owns 65,401 shares of the medical research company's stock worth $8,786,000 after buying an additional 23,466 shares during the last quarter. Investment Management Corp of Ontario boosted its stake in shares of Agilent Technologies by 7.9% in the fourth quarter. Investment Management Corp of Ontario now owns 10,443 shares of the medical research company's stock worth $1,403,000 after buying an additional 762 shares during the last quarter. Finally, Iron Triangle Partners LP purchased a new position in Agilent Technologies during the fourth quarter worth approximately $80,110,000.
Insider Buying and Selling
In other news, Director Daniel K. Podolsky sold 1,819 shares of the company's stock in a transaction on Monday, March 31st. The stock was sold at an average price of $116.46, for a total value of $211,840.74. Following the sale, the director now directly owns 35,737 shares in the company, valued at $4,161,931.02. This represents a 4.84% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, VP Rodney Gonsalves sold 1,908 shares of the company's stock in a transaction on Monday, March 17th. The shares were sold at an average price of $121.98, for a total value of $232,737.84. Following the completion of the sale, the vice president now owns 21,786 shares in the company, valued at $2,657,456.28. This represents a 8.05% decrease in their ownership of the stock. The disclosure for this sale can be found here.
Agilent Technologies Stock Performance
A traded up $0.04 during trading on Tuesday, hitting $113.48. 2,245,772 shares of the stock were exchanged, compared to its average volume of 1,906,204. The firm has a market capitalization of $32.35 billion, a P/E ratio of 26.09, a PEG ratio of 3.21 and a beta of 1.27. Agilent Technologies, Inc. has a 1-year low of $96.43 and a 1-year high of $154.95. The stock has a fifty day moving average price of $110.31 and a two-hundred day moving average price of $127.99. The company has a quick ratio of 1.66, a current ratio of 2.20 and a debt-to-equity ratio of 0.56.
Agilent Technologies (NYSE:A - Get Free Report) last released its earnings results on Wednesday, February 26th. The medical research company reported $1.31 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.27 by $0.04. The business had revenue of $1.68 billion for the quarter, compared to analyst estimates of $1.67 billion. Agilent Technologies had a return on equity of 25.56% and a net margin of 19.27%. As a group, sell-side analysts predict that Agilent Technologies, Inc. will post 5.54 earnings per share for the current year.
Agilent Technologies Dividend Announcement
The firm also recently disclosed a quarterly dividend, which was paid on Wednesday, April 23rd. Investors of record on Tuesday, April 1st were issued a dividend of $0.248 per share. This represents a $0.99 dividend on an annualized basis and a yield of 0.87%. The ex-dividend date was Tuesday, April 1st. Agilent Technologies's dividend payout ratio is presently 22.76%.
Analyst Upgrades and Downgrades
A number of equities analysts have issued reports on A shares. Robert W. Baird lowered their price target on Agilent Technologies from $161.00 to $159.00 and set an "outperform" rating on the stock in a research report on Thursday, February 27th. Jefferies Financial Group reduced their price objective on Agilent Technologies from $135.00 to $116.00 and set a "hold" rating on the stock in a research report on Monday, April 21st. TD Cowen lifted their price objective on Agilent Technologies to $135.00 and gave the stock a "buy" rating in a research report on Thursday, April 10th. Wells Fargo & Company reduced their price objective on Agilent Technologies from $155.00 to $135.00 and set an "overweight" rating on the stock in a research report on Thursday, April 17th. Finally, Barclays reduced their price objective on Agilent Technologies from $138.00 to $115.00 and set an "equal weight" rating on the stock in a research report on Thursday, April 10th. Seven equities research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company's stock. According to data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and an average target price of $143.00.
Get Our Latest Stock Report on Agilent Technologies
Agilent Technologies Profile
(
Free Report)
Agilent Technologies, Inc provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The company operates in three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate reader; laboratory software; information management and analytics; laboratory automation and robotic systems; dissolution testing; and vacuum pumps, and measurement technologies.
Further Reading
Before you consider Agilent Technologies, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Agilent Technologies wasn't on the list.
While Agilent Technologies currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.
Get This Free Report
